
Originally Posted by
Deep_Fried
I just want to point out the misinformation regarding Cabergoline and Bromocriptine. Both of these compounds are Dopamine agonists, especially the D2 receptor.
Dopamine agonists work at the pituitary D2 receptors to inhibit PROLACTIN secretion, and have nothing to do with controlling PROGESTERONE or PROGESTIN action at the Progesterone receptor (PGRr), as this is the method of action of 19nor compounds such as Deca and Tren.
Controlling Prolactin levels is good if they are elevated and a contributing factor to PRL mediated mammary tissue stimulation.
The truth is that Mammry tissue growth, proliferation and differentiation is controlled by the balance/interaction of all 3 hormones: Estrogen, Progesterone, and Prolactin.
Estrogen is responsible for proliferation of mammry gland tissue. Progesterone is also responsible for branching and growth of lobuloalveolar tissue as well. Prolactin contributes to this as well as the lactogenesis phase of mammary tissue development.
Estrogen is responsible for upregulation of the Progesterone receptor (PGRr), thus keeping E under control will directly limit the footprint that Progesterone can take action on as well. If Prolactin is above normal, lowering it can also contibute beneficially.
On that note, AI such as Arimidex, Aromasin or Letrozole is the best bet when dealing with 19nor compounds as the reduction in E will be advantageous in keeping PGR gyno in check as well.
A SERM such as Nolvadex is a VERY BAD choice when running 19nors. Tamoxifen has been documented in studies in producing the same upregulation of the Progesterone receptor just as Estrogen does via the E2 receptor. Even though it suppresses the majority of E's direct action, the upregulation of PGR receptors is counterproductive to keeping total gyno at bay especially Progestin stimulated gyno.
Hope some of this info is usefull.
Take Care.